AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NOXOPHARM LTD

0.068

+0.0057.94%

Volume:724.12K

Turnover:48.43K

Market Cap:19.87M

PE:-8.58

High:0.069

Open:0.065

Low:0.065

Close:0.063

Loading ...

Overview Company News Filings

Company Profile

Company Name:

NOXOPHARM LTD

Exchange:

ASX

Establishment Date:

2015

Employees:

- -

Office Location:

60 Linksley Avenue,Glenhaven,New South Wales,Australia

Website:

http://www.noxopharm.com

Zip Code:

2156

Phone:

Fax:

- -

Introduction:

Noxopharm Limited, a drug development company, focuses on the research and development of drugs to enhance radiotherapy in Australia and internationally. It primarily develops Veyonda, an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also focuses on developing NYX-330, a PCSK9-inhibitor and LDL-cholesterol-lowering drug; NYX-104, a neuroprotectant that protects the brain from further damage after stroke and traumatic brain injury; and NYX-205, an anti-inflammatory drug for the treatment of nerve tissue inflammation. In addition, it develops anti-autoimmune drugs, such as IRAK4 and TPL2 inhibitors. Noxopharm Limited has a clinical alliance with GenesisCare for the combined therapy of Veyonda and 177Lu-PSMA. The company was incorporated in 2015 and is based in Gordon, Australia.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NOX.AU/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NOX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NOX.AU\",,,,,undefined,":{"symbol":"NOX.AU","market":"AU","secType":"STK","nameCN":"NOXOPHARM LTD","latestPrice":0.068,"timestamp":1752819120000,"preClose":0.063,"halted":0,"volume":724123,"delay":0,"nameEN":"NOXOPHARM LTD","floatShares":195506720,"shares":292237950,"eps":-0.007925,"marketStatus":"Market Closed","change":0.005,"latestTime":"07-18 16:12:00 AEST","open":0.065,"high":0.069,"low":0.065,"amount":48426,"amplitude":0.063492,"askPrice":0.068,"askSize":2284,"bidPrice":0.067,"bidSize":30000,"shortable":3,"etf":0,"ttmEps":-0.007925,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1753056000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.063,"openAndCloseTimeList":[[1752796800000,1752818400000]],"volumeRatio":1.5682911606777759,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NOX.AU\",,,,,undefined,":{"symbol":"NOX.AU","floatShares":195506720,"roa":"-45.58%","roe":"-42.50%","lyrEps":-0.012243,"volumeRatio":1.5682911606777759,"shares":292237950,"dividePrice":0,"high":0.069,"amplitude":0.063492,"preClose":0.063,"low":0.065,"week52Low":0.043,"pbRate":"4.60","psRate":"8.48","week52High":0.15,"institutionHeld":0,"latestPrice":0.068,"committee":0.858506,"eps":-0.007925,"divideRate":0,"volume":724123,"delay":0,"ttmEps":-0.007925,"open":0.065,"prevYearClose":0.093,"prevWeekClose":0.044,"prevMonthClose":0.054,"prevQuarterClose":0.054,"fiveDayClose":0.044,"twentyDayClose":0.06,"sixtyDayClose":0.077},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":346635783,"yearFounded":2015,"address":"60 Linksley Avenue,Glenhaven,New South Wales,Australia","zipCode":"2156","officePhone":"61 2 9144 2223"},"stockCompanyDetail":{"websiteUrl":"http://www.noxopharm.com","stockEarnings":[{"period":"1week","weight":0.5455},{"period":"1month","weight":0.0462},{"period":"3month","weight":-0.2},{"period":"6month","weight":-0.236},{"period":"1year","weight":-0.0556},{"period":"ytd","weight":-0.2688}],"compareEarnings":[{"period":"1week","weight":0.0051},{"period":"1month","weight":0.0141},{"period":"3month","weight":0.0788},{"period":"6month","weight":0.1393},{"period":"1year","weight":0.2056},{"period":"ytd","weight":0.1562}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Noxopharm Limited, a drug development company, focuses on the research and development of drugs to enhance radiotherapy in Australia and internationally. It primarily develops Veyonda, an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also focuses on developing NYX-330, a PCSK9-inhibitor and LDL-cholesterol-lowering drug; NYX-104, a neuroprotectant that protects the brain from further damage after stroke and traumatic brain injury; and NYX-205, an anti-inflammatory drug for the treatment of nerve tissue inflammation. In addition, it develops anti-autoimmune drugs, such as IRAK4 and TPL2 inhibitors. Noxopharm Limited has a clinical alliance with GenesisCare for the combined therapy of Veyonda and 177Lu-PSMA. The company was incorporated in 2015 and is based in Gordon, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.222222,"avgChangeRate":0.000496},{"month":2,"riseRate":0.222222,"avgChangeRate":-0.100187},{"month":3,"riseRate":0.222222,"avgChangeRate":0.001363},{"month":4,"riseRate":0.666667,"avgChangeRate":0.008581},{"month":5,"riseRate":0,"avgChangeRate":-0.179589},{"month":6,"riseRate":0.666667,"avgChangeRate":0.14806},{"month":7,"riseRate":0.375,"avgChangeRate":-0.010209},{"month":8,"riseRate":0.666667,"avgChangeRate":0.02435},{"month":9,"riseRate":0.555556,"avgChangeRate":0.395336},{"month":10,"riseRate":0.444444,"avgChangeRate":0.117568},{"month":11,"riseRate":0.111111,"avgChangeRate":-0.137973},{"month":12,"riseRate":0.444444,"avgChangeRate":0.02368}],"exchange":"ASX","name":"NOXOPHARM LTD","nameEN":"NOXOPHARM LTD"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"NOX.AU\",market:\"AU\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NOX.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NOX.AU\",market:\"AU\",,,undefined,":[]}}